帕利哌酮缓释片与盐酸哌罗匹隆片治疗精神分裂症患者临床疗效研究
Clinical efficacy of paliperidone sustained release tablets and piperazone hydrochloride tablets in the treatment of schizophrenia
ES评分 0
| DOI |
| 刊名 |
Journal of International Psychiatry
|
| 年，卷(期) |
2022, 49(2) |
| 作者 |
|
| 作者单位 |
沈阳市精神卫生中心 ;
|
| 摘要 |
[摘要]比较帕利哌酮缓释片与盐酸哌罗匹隆片治疗精神分裂症患者的疗效和安全性。方法 将70例精神分裂症患者随机分为帕利哌酮组和哌罗匹隆组。两组患者入组治疗前均停用抗精神病药至少2周。哌罗匹隆组患者给予盐酸哌罗匹隆片口服，初始剂量8毫克，2周后逐渐增加至12-48毫克；帕利哌酮组给予帕利哌酮缓释片，初始剂量3毫克，2周后剂量逐渐增加至6-9毫克。两组患者疗程均为8周。观察两组患者治疗前、治疗后阳性和阴性症状量表(Positive And Negative Syndrome Scale PANSS)、副反应量表（Treatment Emergent Symptom Scale TESS）评分变化。结果 治疗前，两组患者的PANSS量评分对比差异无统计学意义。治疗后，帕利哌酮组PANSS量表分低于哌罗匹隆组，帕利哌酮组有效率高于哌罗匹隆组，差异具有统计学意义(P＜0.05)。结论 帕利哌酮在改善精神分裂症患者阳性、阴性症状方面优于哌罗匹隆。帕利哌酮更容易出现体重增加及泌乳素升高，哌罗匹隆更容易出现静坐不能。
|
| Abstract |
[Abstract] Objective To compare the efficacy and safety of paliperidone sustained-release tablets and peropirone hydrochloride tablets in the treatment of schizophrenia. Methods 70 patients with schizophrenia were randomly divided into paliperidone group and piperazone group. Antipsychotics were discontinued for at least 2 weeks before treatment in both groups. The patients in the piperazone group were given the initial dose of 8 mg and gradually increased to 12-48 mg after 2 weeks; the paliperidone group was given paliperidone sustained-release tablets, the initial dose was 3 mg, and the dose gradually increased to 6-9 mg after 2 weeks. The course of treatment was 8 weeks in both groups. The changes of positive and Negative Syndrome Scale (PANSS) and Treatment Emergent Symptom Scale (TESS) scores were observed before and after treatment. Results before treatment, there was no significant difference in PANSS score between the two groups. After treatment, the PANSS score of paliperidone group was lower than that of piperazone group, and the effective rate of paliperidone group was higher than that of piperazone group, the difference was statistically significant (P < 0.05). Conclusion paliperidone is better than piperazone in improving the positive and negative symptoms of schizophrenia. Paliperidone was more prone to weight gain and prolactin, while piperazone was more prone to cant sit still.
|
| 关键词 |
[关键词]帕利哌酮；哌罗匹隆；精神分裂症
|
| KeyWord |
[Key words] paliperidone; piperazone; schizophrenia
|
| 基金项目 |
|
| 页码 |
256-258 |
商月骄*.
帕利哌酮缓释片与盐酸哌罗匹隆片治疗精神分裂症患者临床疗效研究 [J].
国际精神病学杂志.
2022; 49; (2).
256 - 258.